STEVENSVILLE, Md., July 26, 2011 /PRNewswire-USNewswire/ -- Vapotherm announced today the launch of Flowrest®, a High Flow Therapy device developed specifically for homecare and other low acuity environments. The initial launch will focus on the U.S. and European markets.
Vapotherm's Flowrest® is designed specifically for chronic respiratory patients in home and other extended care environments. According to the World Health Organization, chronic respiratory diseases impact hundreds of millions of people worldwide, with asthma and COPD alone totaling almost 300 million globally. Other chronic conditions include allergic rhinitis, pulmonary fibrosis and pulmonary hypertension. In the U.S. alone, COPD affects more than 16 million and over 1 million patients are prescribed long-term oxygen therapy. Flowrest® is indicated to deliver heated, humidified breathing gases via nasal cannula at flow rates from 15 to 35 liters per minute.
"In response to pre-launch demand, we are excited to begin shipping Flowrest® to our customers in the U.S. and Europe," said Nick Macmillan, Home Care Segment Manager at Vapotherm. "The Flowrest® provides patients with a new option for respiratory assistance that overcomes the well documented issues associated with mask therapies including problems with patient compliance and comfort. Through our patented technology, we have empowered the simple and comfortable nasal cannula to provide higher levels of respiratory support."
Robert Storey, CEO of Vapotherm, commenting on the launch stated, "We wanted to provide a solution to the constant requests we received from hospital customers for a homecare option. Worldwide, health care systems are looking for ways to get patients out of the hospital faster and sustain them at home to minimize the risk that they will have to return to the hospital. Flowrest® is our answer to the continuity of care in Hi